| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003985 | American Journal of Ophthalmology | 2010 | 8 Pages |
Abstract
This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Magda Gharbiya, Rosalia Giustolisi, Francesca Allievi, Nicoletta Fantozzi, Luigi Mazzeo, Vittorio Scavella, Corrado Balacco Gabrieli,